Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Advanced Medical Solutions Group's Beta is 0.5497.
Advanced Medical Solutions Group (LSE:AMS) Beta Explanation
Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.
Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
Advanced Medical Solutions Group Beta Related Terms
Advanced Medical Solutions Group Beta Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Beta, along with its competitors' market caps and Beta data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Beta vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Beta distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Beta falls into.
Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.
Advanced Medical Solutions Group (LSE:AMS) has a Beta of 0.5497 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Advanced Medical Solutions Group and its competitors.
Is Advanced Medical Solutions Group's Beta too high?
Advanced Medical Solutions Group's current Beta is 0.5497. Overall, Advanced Medical Solutions Group has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Beta compare to ISRG and BDX?
Advanced Medical Solutions Group's Beta of 0.5497 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Advanced Medical Solutions Group and its competitors. Advanced Medical Solutions Group's current Beta is 0.5497. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (LSE:AMS) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.69, compared to a current price of £2.79 — trading 24.5% below its estimated fair value. The current Beta is 0.5497. Advanced Medical Solutions Group's overall GF Score™ is 89/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Advanced Medical Solutions Group (LSE:AMS), the current Beta is 0.5497 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (LSE:AMS) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.79 is trading 24.5% below its estimated GF Value™ of £3.69.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for LSE:AMS:
Beta: 0.5497
GF Value™: £3.69 vs. price of £2.79 (24.5% below fair value)
No single metric tells the full story. See the LSE:AMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group Business Description
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
89GF Score
Get the complete analysis for LSE:AMS
Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AMS has been successfully added to your 
